Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$12 Mln
P/E Ratio
--
P/B Ratio
0.2
Industry P/E
--
Debt to Equity
0.04
ROE
-0.54 %
ROCE
-51.75 %
Div. Yield
0 %
Book Value
1.81
EPS
-1.25
CFO
$37.15 Mln
EBITDA
$18.96 Mln
Net Profit
$5.25 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Co-Diagnostics (CODX)
| -50.00 | -18.66 | -52.59 | -67.39 | -57.54 | -51.10 | -- |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Co-Diagnostics (CODX)
| -43.35 | -47.22 | -71.78 | -3.98 | 938.87 | -39.92 | -43.38 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.28 | 10,289.47 | 14.38 | 12.69 | |
| 70.06 | 9,544.04 | 92.52 | 2.52 | |
| 152.07 | 8,064.21 | -- | -25.23 | |
| 277.22 | 10,728.90 | 773.26 | 1.2 |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The... company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Address: 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109 Read more
Chairman & CEO
Mr. Dwight H. Egan
Chairman & CEO
Mr. Dwight H. Egan
Headquarters
Salt Lake City, UT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Co-Diagnostics Inc (CODX) stood at $ 64 Mln as on 31-Dec-24
The share price of Co-Diagnostics Inc (CODX) is $0.38 (NASDAQ) as of 22-Apr-2025 16:00 EDT. Co-Diagnostics Inc (CODX) has given a return of -57.54% in the last 3 years.
Co-Diagnostics Inc (CODX) has a market capitalisation of $ 12 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Co-Diagnostics Inc (CODX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Co-Diagnostics Inc (CODX) and enter the required number of quantities and click on buy to purchase the shares of Co-Diagnostics Inc (CODX).
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Address: 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109
The CEO & director of Mr. Dwight H. Egan. is Co-Diagnostics Inc (CODX), and CFO & Sr. VP is Mr. Dwight H. Egan.
There is no promoter pledging in Co-Diagnostics Inc (CODX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Co-Diagnostics Inc. (CODX) | Ratios |
|---|---|
|
Return on equity(%)
|
-53.65
|
|
Operating margin(%)
|
-1023.75
|
|
Net Margin(%)
|
-961.37
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Co-Diagnostics Inc (CODX) was $0 Mln.
$0.02
(
